Compare GKOS & HRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | HRL |
|---|---|---|
| Founded | 1998 | 1891 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Meat/Poultry/Fish |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 11.2B |
| IPO Year | 2015 | 1994 |
| Metric | GKOS | HRL |
|---|---|---|
| Price | $180.54 | $20.55 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 10 |
| Target Price | ★ $199.31 | $25.31 |
| AVG Volume (30 Days) | 979.8K | ★ 4.7M |
| Earning Date | 10-28-2026 | 12-03-2026 |
| Dividend Yield | N/A | ★ 5.68% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | $507,442,000.00 | ★ $12,106,160,000.00 |
| Revenue This Year | $36.30 | $0.18 |
| Revenue Next Year | $23.25 | $1.84 |
| P/E Ratio | ★ N/A | $28.59 |
| Revenue Growth | ★ 32.33 | 1.55 |
| 52 Week Low | $80.91 | $18.96 |
| 52 Week High | $191.62 | $26.60 |
| Indicator | GKOS | HRL |
|---|---|---|
| Relative Strength Index (RSI) | 65.62 | 50.38 |
| Support Level | $175.04 | $20.38 |
| Resistance Level | $184.68 | $22.03 |
| Average True Range (ATR) | 6.45 | 0.39 |
| MACD | 1.90 | 0.18 |
| Stochastic Oscillator | 80.18 | 67.36 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and became a branded food company. The firm sells its wares through multiple channels, including US retail (61.6% of fiscal 2025 sales), US foodservice (32.6%), and international (less than 6%). By product, 73% of fiscal 2025 sales were from perishable food and 27% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.